Category: Parkinsonism, Others
Objective: To assess safety and efficacy of COVID-19 vaccines against SARS-CoV-2 in people with Parkinson’s disease.
Background: Different forms of vaccines have been developed to prevent the SARS-CoV-2 virus and subsequent COVID-19 disease. These vaccines can help to mitigate risk of becoming infected with SARS-CoV-2, which can lead to serious, life-threating disease to people with Parkinson’s disease.
Method: The study included patients with Parkinson’s disease
who received a full course of vaccination, including a booster dose of the
vaccine. All patients were followed up for 6 months after receiving a booster dose
of the vaccine. We collected patient data using a standard form. The form contained
questions about patient demographics, current anti-Parkinson’s drugs, and information about vaccinations and side effects.
Results: A total of 38 people with PD participated in the study. Of the 38 patients, 23 (60.5%) were male and the remaining 15 (39.5%) were female. In addition, general and local post-vaccination side effects were observed in patients. When receiving the first two doses most commonly reported adverse events were (in descending order) headache, fatigue, myalgia, fever and chills. Of the local reactions in patients, pain, redness and itching were observed at the injection site. All common and local reactions were mild and resolved within 7 days after receiving the vaccine. When receiving booster dose of vaccine after 6 month, common adverse events were headache and fatigue; local reactions were pain and redness. All common and local reactions resolved within 3 days after receiving booster dose of vaccine.
Conclusion: Several neurological complications have been reported following SARS-CoV-2 vaccination, without a clear causal relationship ever being verified, including some cases of worsening PD symptoms. In our study all common and local adverse events were transient and benign nature. Deteriorated PD symptoms and new-onset movement disorders following vaccination were not observed.
To cite this abstract in AMA style:
J. Salimjonov, N. Rashidova, K. Khalimova, R. Matmurodov. Vaccination from Covid-19 in people with Parkinson`s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/vaccination-from-covid-19-in-people-with-parkinsons-disease/. Accessed May 16, 2025.« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/vaccination-from-covid-19-in-people-with-parkinsons-disease/